系统性幼年特发性关节炎(sJIA)的特征是促炎细胞因子的过度产生。作为抗IL-1药物,canakinumab已在美国和欧洲获得批准用于治疗≥2岁的sJIA患者.然而,canakinumab的使用在中国从未报道过。在这项研究中,我们旨在评估canakinumab在中国sJIA患者中的疗效和安全性.
■本研究共纳入了11例接受卡纳单抗治疗的sJIA患者。从病历中回顾性收集临床数据。通过系统性幼年关节炎疾病活动评分(sJADAS)评价疗效。在canakinumab开始时进行随访,在第1、3、6、9和12个月或最后一次随访时。
■在11名患者中,91.0%(10/11)以前曾接受过托珠单抗治疗。canakinumab的平均持续时间为9(3-18)个月。45.5%(5/11)的患者表现出完全缓解,45.5%(5/11)显示部分反应,9.0%(1/11)无反应。18.2%(2/11)在使用canakinumab治疗期间出现疾病发作。81.8%(9/11)的患者成功减少了糖皮质激素的剂量,六个停止皮质类固醇。45.6%(5/11)的患者出现感染。在canakinumab治疗期间没有发生严重不良事件。
■Canakinumab可能对中国sJIA患者有效且可耐受,有助于减少皮质类固醇的剂量。然而,需要对大样本进行额外的研究以评估其有效性和安全性。
UNASSIGNED: Systemic juvenile idiopathic arthritis (sJIA) is characterized by excessive production of proinflammatory cytokines. As an anti-IL-1 agent,
canakinumab has been approved in the USA and Europe for the treatment of sJIA patients aged ≥2 years. However, the use of
canakinumab has never been reported in China. In this study, we aimed to assess the efficacy and safety of
canakinumab in Chinese patients with sJIA.
UNASSIGNED: A total of 11 patients with sJIA who were treated with
canakinumab were included in this study. Clinical data were collected retrospectively from medical records. Efficacy was evaluated by the systemic juvenile arthritis disease activity score (sJADAS). The follow-up was performed at canakinumab initiation, at months 1, 3, 6, 9 and 12, or at the last follow-up.
UNASSIGNED: Of the 11 patients enrolled, 91.0% (10/11) had previously received treatment with tocilizumab. The mean duration of canakinumab was 9 (3-18) months. 45.5% (5/11) of patients showed complete response, 45.5% (5/11) showed partial response, and 9.0% (1/11) showed no response. 18.2% (2/11) experienced disease flare during the treatment with canakinumab. 81.8% (9/11) of patients successfully reduced the dose of corticosteroids, with six discontinuing corticosteroids. 45.6% (5/11) of patients experienced infection. No serious adverse events occurred during the treatment with
canakinumab.
UNASSIGNED: Canakinumab may be effective and tolerable for Chinese sJIA patients, helping to reduce the dosage of corticosteroids. However, additional researches on large samples are required to evaluate its efficacy and safety.